Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review

被引:2
|
作者
Ahmad, Zeeshanuddin [1 ]
Jain, Amar [1 ]
Mehta, Nikhil [1 ]
Saldanha, Elroy [1 ]
Patel, Dhruv [1 ]
Desai, Sanjay M. [1 ]
机构
[1] Sri Aurobindo Med Coll & Post Grad Inst, Dept Surg Oncol, Indore, Madhya Pradesh, India
关键词
Epithelial ovarian cancer (EOC); Primary cytoreductive surgery (PCS); Interval debulking surgery (IDS); Neoadjuvant chemotherapy (NACT); ADVANCED-STAGE OVARIAN; EXPLORATORY ANALYSIS; SURVIVAL; CARCINOMA; TIME;
D O I
10.1007/s40944-018-0253-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveTo compare theoverall survival of women with advanced-stage EOC treated by PCS versus NACT followed by IDS.Design, Setting, and ParticipantsRetrospective study of women with stage IIB-IVA ovarian carcinoma FIGO staging diagnosed between 2016 and 2018 treated at Department of Surgical Oncology, Sri Aurobindo Medical College and Post Graduate Institute, Indore.ExposuresInitial treatment approach of PCS versus NACT+IDS, examined using an intent-to-treat analysis.ResultsThe median follow-up was 18months (10-36months) in both groups. The median overall survival was 38months in PCS group and 31months in NACT group. Postoperative complications were seen more often in PCS group (11.3%) against 3.33% in NACT group. Patients with residual disease (microscopic and macroscopic residual disease) had poorer prognosis.ConclusionsPrimary cytoreductive surgery is associated with improved survival compared with NACT in otherwise healthy women with bulky epithelial ovarian. The biggest risk associated with the use of NACT is that patients with significant side effects and refractory disease will lose the opportunity for initial surgery. The lower survival in women receiving NACT can be owed to limited performance status in women undergoing NACT.
引用
收藏
页数:4
相关论文
共 50 条
  • [1] Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review
    Zeeshanuddin Ahmad
    Amar Jain
    Nikhil Mehta
    Elroy Saldanha
    Dhruv Patel
    Sanjay M. Desai
    Indian Journal of Gynecologic Oncology, 2019, 17
  • [2] Neoadjuvant chemotherapy followed by interval debulking surgery versus primary debulking surgery in the advanced epithelial ovarian cancer - a retrospective cohort study
    Maricic, Slobodan
    Mandic, Aljosa
    Dejanovic, Ninoslav
    Kladar, Nebojsa
    Popovic, Marina
    Ivkovic-Kapicl, Tatjana
    Gutic, Bojana
    Kokanov, Dunja
    VOJNOSANITETSKI PREGLED, 2021, 78 (11) : 1193 - 1199
  • [3] Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer
    Vergote, Ignace
    Amant, Frederic
    Kristensen, Gunnar
    Ehlen, Tom
    Reed, Nick S.
    Casado, Antonio
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S88 - S92
  • [4] Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Zheng, Hong
    Gao, Yu-Nong
    CHINESE JOURNAL OF CANCER RESEARCH, 2012, 24 (04) : 304 - 309
  • [5] Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Propensity-matched Analysis
    Siesto, Gabriele
    Cavina, Raffaele
    Romano, Fabrizio
    Vitobello, Domenico
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (03): : 280 - 285
  • [6] Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection
    Gill, Sarah E.
    McGree, Michaela E.
    Weaver, Amy L.
    Cliby, William A.
    Langstraat, Carrie L.
    GYNECOLOGIC ONCOLOGY, 2017, 144 (02) : 266 - 273
  • [7] Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer
    Nishio, Shin
    Ushijima, Kimio
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (04) : 379 - 386
  • [8] Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer
    da Costa, Alexandre A. B. A.
    Valadares, Camila V.
    Baiocchi, Glauco
    Mantoan, Henrique
    Saito, Augusto
    Sanches, Solange
    Guimaraes, Andreia P.
    Achatz, Maria Isabel W.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S971 - S978
  • [9] Primary debulking surgery or neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Hong Zheng
    Yu-Nong Gao
    ChineseJournalofCancerResearch, 2012, 24 (04) : 304 - 309
  • [10] Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
    Rauh-Hain, J. Alejandro
    Rodriguez, Noah
    Growdon, Whitfield B.
    Goodman, A. K.
    Boruta, David M., II
    Horowitz, Neil S.
    del Carmen, Marcela G.
    Schorge, John O.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (03) : 959 - 965